GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GreenLight Biosciences Holdings PBC (NAS:GRNA) » Definitions » Net Cash per Share

GreenLight Biosciences Holdings PBC (GreenLight Biosciences Holdings PBC) Net Cash per Share : $-0.39 (As of Mar. 2023)


View and export this data going back to 2022. Start your Free Trial

What is GreenLight Biosciences Holdings PBC Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). GreenLight Biosciences Holdings PBC's Net Cash per Share for the quarter that ended in Mar. 2023 was $-0.39.

The historical rank and industry rank for GreenLight Biosciences Holdings PBC's Net Cash per Share or its related term are showing as below:

During the past 4 years, the highest Price-to-Net-Cash Ratio of GreenLight Biosciences Holdings PBC was 48.15. The lowest was 0.00. And the median was 29.60.

GRNA's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 3.87
* Ranked among companies with meaningful Price-to-Net-Cash only.

GreenLight Biosciences Holdings PBC Net Cash per Share Historical Data

The historical data trend for GreenLight Biosciences Holdings PBC's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GreenLight Biosciences Holdings PBC Net Cash per Share Chart

GreenLight Biosciences Holdings PBC Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Net Cash per Share
-0.95 -1.64 -0.50 -0.21

GreenLight Biosciences Holdings PBC Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 -0.33 0.21 -0.21 -0.39

Competitive Comparison of GreenLight Biosciences Holdings PBC's Net Cash per Share

For the Biotechnology subindustry, GreenLight Biosciences Holdings PBC's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GreenLight Biosciences Holdings PBC's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GreenLight Biosciences Holdings PBC's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where GreenLight Biosciences Holdings PBC's Price-to-Net-Cash falls into.



GreenLight Biosciences Holdings PBC Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

GreenLight Biosciences Holdings PBC's Net Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as

Net Cash per Share (A: Dec. 2022 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(68.097-100.536-0)/151.587
=-0.21

GreenLight Biosciences Holdings PBC's Net Cash per Share for the quarter that ended in Mar. 2023 is calculated as

Net Cash per Share (Q: Mar. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(32.35-91.753-0)/151.681
=-0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GreenLight Biosciences Holdings PBC  (NAS:GRNA) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


GreenLight Biosciences Holdings PBC Net Cash per Share Related Terms

Thank you for viewing the detailed overview of GreenLight Biosciences Holdings PBC's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


GreenLight Biosciences Holdings PBC (GreenLight Biosciences Holdings PBC) Business Description

Traded in Other Exchanges
N/A
Address
29 Hartwell Avenue, Lexington, MA, USA, 02421
GreenLight Biosciences Holdings PBC is a pre-commercial stage synthetic biology company with a proprietary cell-free ribonucleic acid production platform for the discovery, development, and commercialization of high-performing products to promote healthier plants, foods, and people. The company is developing RNA products for plant and life science applications to advance crop management, plant protection, animal health, vaccine development, and pandemic preparation.
Executives
Deval L Patrick other: See Remarks BAIN CAPITAL, LLC, 200 CLARENDON STREET, BOSTON MA 02116
Dennis A. Clarke other: Member of 13D group owning 10% 6 FERNWAY TERRACE, WINCHESTER MA 01890
Cummings Foundation, Inc. other: Member of 13D group owning 10% 200 WEST CUMMINGS PARK, WOBURN MA 01801
Eric Senior Anderson other: Member of 13D group owning 10% 25 N HILL ROAD, WESTOVER MA 01886
Mls Capital Fund Ii Lp other: See remarks C/O MLSC II (GP) (LABUAN) LLP, ONE MARKET ST SUITE 3525, SAN FRANCISCO CA 94105
Chelt Trading Ltd other: Member of 13D Group C/O FOX HORAN & CAMERINI LLP, 885 3RD AVENUE, 17TH FLOOR, NEW YORK NY 10022
Highview Trust other: Member of 13D Group C/O FOX HORAN & CAMERINI LLP, 885 THIRD AVENUE, 17TH FLOOR, NEW YORK NY 10022
Montealegre Lacayo Jaime Javier other: Member of 13D Group APARTADO 15-1250, ESCAZU G2
Furneaux Capital Holdco, Llc other: Member of 13D group 1 MARINA PARK DRIVE, BOSTON MA 02210
Lewis & Clark Plant Sciences Fund I, Lp other: Member of 13D group 120 S. CENTRAL AVENUE, SUITE 1000, ST. LOUIS MO 63105
Lewis & Clark Ventures I, Lp other: Member of 13D group 120 S. CENTRAL AVENUE, SUITE 1000, ST. LOUIS MO 63105
Matthew Allen Walker director, 10 percent owner C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Martha Schlicher director C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Marta Ortega-valle other: Member of 10% owner group C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Builders Vision, Llc 10 percent owner 110 NW 2ND STREET SUITE 300, BENTONVILLE AR 72712

GreenLight Biosciences Holdings PBC (GreenLight Biosciences Holdings PBC) Headlines

From GuruFocus

Co-developer of COVID-19 Vaccine Joins GreenLight Advisory Board

By GuruFocusNews GuruFocusNews 03-29-2022